Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: wvalx who wrote (22494)	9/17/1999 2:05:00 AM
From: 777 Captain	Read Replies (2) \| Respond to of 23519

Recently contacted AZ, both in the US and Europe regarding VVUS. In US, they knew very little about the company, apparently current sales don't encourage much interest. Not on their "radar screens," as they put it, in the US. Europe is a somewhat different story. To date, AZ has launched Muse in a little more than 10 countries. Some near term expected launches include the Netherlands and Spain. Muse is now included as a part of oncology. Marketed along with other drugs in the treatment of prostrate cancer, primarily through urologists. FWIW: I'm expecting a response shortly regarding other issues that I raised, e.g., Germany, Alibra, et. al. Hope to hear something tomorrow, or some time next week. I'll post it when I receive it. Question: can anybody out there tell me how to post an e-mail response to this thread - in layman's terms? I'm using Windows 98. Regards to all.